Phase 3 trial data show that obinutuzumab significantly reduces disease activity in very active extrarenal lupus.

McEwen Inc. (NYSE/TSX: MUX) today announced its fourth quarter (Q4) and full year results for the period ended December 31, 2025, along with an update on its development projects as the Company looks ...